Clinical Trial Update: To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating intravesical Disitamab Vedotin (RC48) for high-risk non-muscle invasive bladder cancer expressing HER2, with recruitmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• RC48 (disitamab vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: High-risk Non-muscle Invasive Bladder Cancer | Phase 1, Phase 2 | Status: RECRUITING